MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors

Matthew A. Smith, Thomas Licata, Aliya Lakhani, Marileila Varella Garcia, Hans Ulrich Schildhaus, Vincent Vuaroqueaux, Balazs Halmos, Alain C. Borczuk, Y. Ann Chen, Benjamin C. Creelan, Theresa A. Boyle, Eric B. Haura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors dependent on MET and could add additional precision beyond genomic assessments. Experimental Design: We used biochemical approaches, cellular viability studies, and proximity ligation assays to assess MET dependence. We examined MET signaling complexes in lung cancer patient specimens (N ¼ 406) and patient-derived xenograft (PDX) models of solid tumors (N ¼ 308). We evaluated response to crizotinib in a MET-amplified cohort of PDX models of lung cancer (N ¼ 6) and provide a case report of a lung cancer patient harboring a Dexon14 MET splice variant. Results: We found the interaction of MET with the adaptor protein GRB2 is necessary for oncogenic survival signaling by MET. MET-GRB2 complexes were identified only within MET-amplified PDX models and patient specimens but exhibit substantial variability. Lack of MET-GRB2 complexes was associated with lack of response to MET TKI in cell lines and PDX models. Presence of MET-GRB2 complexes can further subtype tumors with Dexon14 MET splice variants. Presence of these complexes correlated with response to crizotinib in one patient with Dexon14 MET lacking MET gene amplification. Conclusions: Proximity assays measuring MET-GRB2 signaling complexes provide novel insights into MET-mediated signaling and could complement current clinical genomics-based assay platforms.

Original languageEnglish (US)
Pages (from-to)7084-7096
Number of pages13
JournalClinical Cancer Research
Volume23
Issue number22
DOIs
StatePublished - Nov 15 2017

Fingerprint

Phosphotransferases
Heterografts
Lung Neoplasms
GRB2 Adaptor Protein
Neoplasms
Gene Amplification
Genomics
Ligation
Research Design
Cell Line
Survival
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Smith, M. A., Licata, T., Lakhani, A., Garcia, M. V., Schildhaus, H. U., Vuaroqueaux, V., ... Haura, E. B. (2017). MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors. Clinical Cancer Research, 23(22), 7084-7096. https://doi.org/10.1158/1078-0432.CCR-16-3006

MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors. / Smith, Matthew A.; Licata, Thomas; Lakhani, Aliya; Garcia, Marileila Varella; Schildhaus, Hans Ulrich; Vuaroqueaux, Vincent; Halmos, Balazs; Borczuk, Alain C.; Chen, Y. Ann; Creelan, Benjamin C.; Boyle, Theresa A.; Haura, Eric B.

In: Clinical Cancer Research, Vol. 23, No. 22, 15.11.2017, p. 7084-7096.

Research output: Contribution to journalArticle

Smith, MA, Licata, T, Lakhani, A, Garcia, MV, Schildhaus, HU, Vuaroqueaux, V, Halmos, B, Borczuk, AC, Chen, YA, Creelan, BC, Boyle, TA & Haura, EB 2017, 'MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors', Clinical Cancer Research, vol. 23, no. 22, pp. 7084-7096. https://doi.org/10.1158/1078-0432.CCR-16-3006
Smith, Matthew A. ; Licata, Thomas ; Lakhani, Aliya ; Garcia, Marileila Varella ; Schildhaus, Hans Ulrich ; Vuaroqueaux, Vincent ; Halmos, Balazs ; Borczuk, Alain C. ; Chen, Y. Ann ; Creelan, Benjamin C. ; Boyle, Theresa A. ; Haura, Eric B. / MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 22. pp. 7084-7096.
@article{f14376dd4c2340139b9ce31526c112d7,
title = "MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors",
abstract = "Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors dependent on MET and could add additional precision beyond genomic assessments. Experimental Design: We used biochemical approaches, cellular viability studies, and proximity ligation assays to assess MET dependence. We examined MET signaling complexes in lung cancer patient specimens (N ¼ 406) and patient-derived xenograft (PDX) models of solid tumors (N ¼ 308). We evaluated response to crizotinib in a MET-amplified cohort of PDX models of lung cancer (N ¼ 6) and provide a case report of a lung cancer patient harboring a Dexon14 MET splice variant. Results: We found the interaction of MET with the adaptor protein GRB2 is necessary for oncogenic survival signaling by MET. MET-GRB2 complexes were identified only within MET-amplified PDX models and patient specimens but exhibit substantial variability. Lack of MET-GRB2 complexes was associated with lack of response to MET TKI in cell lines and PDX models. Presence of MET-GRB2 complexes can further subtype tumors with Dexon14 MET splice variants. Presence of these complexes correlated with response to crizotinib in one patient with Dexon14 MET lacking MET gene amplification. Conclusions: Proximity assays measuring MET-GRB2 signaling complexes provide novel insights into MET-mediated signaling and could complement current clinical genomics-based assay platforms.",
author = "Smith, {Matthew A.} and Thomas Licata and Aliya Lakhani and Garcia, {Marileila Varella} and Schildhaus, {Hans Ulrich} and Vincent Vuaroqueaux and Balazs Halmos and Borczuk, {Alain C.} and Chen, {Y. Ann} and Creelan, {Benjamin C.} and Boyle, {Theresa A.} and Haura, {Eric B.}",
year = "2017",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-16-3006",
language = "English (US)",
volume = "23",
pages = "7084--7096",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors

AU - Smith, Matthew A.

AU - Licata, Thomas

AU - Lakhani, Aliya

AU - Garcia, Marileila Varella

AU - Schildhaus, Hans Ulrich

AU - Vuaroqueaux, Vincent

AU - Halmos, Balazs

AU - Borczuk, Alain C.

AU - Chen, Y. Ann

AU - Creelan, Benjamin C.

AU - Boyle, Theresa A.

AU - Haura, Eric B.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors dependent on MET and could add additional precision beyond genomic assessments. Experimental Design: We used biochemical approaches, cellular viability studies, and proximity ligation assays to assess MET dependence. We examined MET signaling complexes in lung cancer patient specimens (N ¼ 406) and patient-derived xenograft (PDX) models of solid tumors (N ¼ 308). We evaluated response to crizotinib in a MET-amplified cohort of PDX models of lung cancer (N ¼ 6) and provide a case report of a lung cancer patient harboring a Dexon14 MET splice variant. Results: We found the interaction of MET with the adaptor protein GRB2 is necessary for oncogenic survival signaling by MET. MET-GRB2 complexes were identified only within MET-amplified PDX models and patient specimens but exhibit substantial variability. Lack of MET-GRB2 complexes was associated with lack of response to MET TKI in cell lines and PDX models. Presence of MET-GRB2 complexes can further subtype tumors with Dexon14 MET splice variants. Presence of these complexes correlated with response to crizotinib in one patient with Dexon14 MET lacking MET gene amplification. Conclusions: Proximity assays measuring MET-GRB2 signaling complexes provide novel insights into MET-mediated signaling and could complement current clinical genomics-based assay platforms.

AB - Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors dependent on MET and could add additional precision beyond genomic assessments. Experimental Design: We used biochemical approaches, cellular viability studies, and proximity ligation assays to assess MET dependence. We examined MET signaling complexes in lung cancer patient specimens (N ¼ 406) and patient-derived xenograft (PDX) models of solid tumors (N ¼ 308). We evaluated response to crizotinib in a MET-amplified cohort of PDX models of lung cancer (N ¼ 6) and provide a case report of a lung cancer patient harboring a Dexon14 MET splice variant. Results: We found the interaction of MET with the adaptor protein GRB2 is necessary for oncogenic survival signaling by MET. MET-GRB2 complexes were identified only within MET-amplified PDX models and patient specimens but exhibit substantial variability. Lack of MET-GRB2 complexes was associated with lack of response to MET TKI in cell lines and PDX models. Presence of MET-GRB2 complexes can further subtype tumors with Dexon14 MET splice variants. Presence of these complexes correlated with response to crizotinib in one patient with Dexon14 MET lacking MET gene amplification. Conclusions: Proximity assays measuring MET-GRB2 signaling complexes provide novel insights into MET-mediated signaling and could complement current clinical genomics-based assay platforms.

UR - http://www.scopus.com/inward/record.url?scp=85034852693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034852693&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-3006

DO - 10.1158/1078-0432.CCR-16-3006

M3 - Article

VL - 23

SP - 7084

EP - 7096

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -